Is Cyclo Therapeutics Inc (CYTH) a Good Buy in the Drug Manufacturers

The 65 rating InvestorsObserver gives to Cyclo Therapeutics Inc (CYTH) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 89 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, CYTH’s 65 overall rating means the stock scores better than 65 percent of all stocks.

CYTH has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on CYTH!

See Full CYTH Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Cyclo Therapeutics Inc Stock Today?

Cyclo Therapeutics Inc (CYTH) stock is up 2.93% while the S&P 500 is down -0.03% as of 10:56 AM on Friday, Nov 17. CYTH has gained $0.04 from the previous closing price of $1.36 on volume of 3,107 shares. Over the past year the S&P 500 has gained 14.20% while CYTH has gained 21.74%. CYTH lost -$1.88 per share the over the last 12 months. Click Here to get the full Stock Report for Cyclo Therapeutics Inc stock.